Результаты поиска

Dimethyl Fumarate and Cobalt Protoporphyrin IX Inhibit Fibromyalgia-like Pain by Modulating Region-Specific Redox Pathways.

Fibromyalgia is a chronic nociplastic pain disorder characterized by widespread pain and affective disturbances, in which oxidative stress and neuroinflammation are now recognized as central pathogenic mechanisms. However, current therapies provide only limited symptomatic relief. This study compared the therapeutic and molecular effects of dimethyl fumarate (DMF), an activator of nuclear factor erythroid 2-related factor 2 (NRF2), and cobalt protoporphyrin IX (CoPP), an inducer of heme oxygenase-1 (HO-1), in a reserpine-induced mouse model of fibromyalgia-like pain. Male and female C57BL/6J m…

Dimethyl fumarate modulates M1/M2 macrophage polarization to ameliorate periodontal destruction by increasing TUFM-mediated mitophagy.

Periodontitis is a common oral disease characterized by progressive alveolar bone resorption and inflammation of the periodontal tissues. Dimethyl fumarate (DMF) has been used in the treatment of various immune-inflammatory diseases due to its excellent anti-inflammatory and antioxidant functions. Here, we investigated for the first time the therapeutic effect of DMF on periodontitis. In vivo studies showed that DMF significantly inhibited periodontal destruction, enhanced mitophagy, and decreased the M1/M2 macrophage ratio. In vitro studies showed that DMF inhibited macrophage polarization to…

Fracture Risk Associated With Dimethyl Fumarate Treatment in Multiple Sclerosis Patients: Population Heterogeneity and Temporal Patterns.

OBJECTIVE: Dimethyl fumarate (DMF) is currently recommended as a first-line therapy for multiple sclerosis (MS). Investigating its adverse events (AEs) holds significant clinical importance. This study aimed to explore the association between DMF and fracture-related AEs. METHODS: Data from the FDA Adverse Event Reporting System (FAERS) database (Q1 2004 to Q3 2024) were analyzed using disproportionality analysis. Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayes Geometric Mean (EBGM) were employed to identify and characterize AEs.…

Сравнительная активность диметилфумаратных производных IDMF в трех моделях, имеющих отношение к множественному склерозу и псориазу.

Диметилфумарат (DMF) — антивоспалительное и иммунорегулирующее лекарство, используемое для лечения множественных склерозов (MS) и псориаза. Его сенсационно-информационная собственность исключает его тематическое использование, что вызывает сожаление в связи с лечением псориаза. Изосорбид ди(метилфумарат) (ИДМФ) (новая производная ДМФ) был синтезирован для того, чтобы обойти эту негативную реакцию и раскрыть потенциал тематических родов, которые могли бы быть полезными для лечения псориаза в субпопуляции псориатических пациентов, страдающих МЗ, а также в целом. Здесь мы сравнили его терапевтиче

Совпадение в аннотации оригинала
Dimethyl fumarate (DMF) is an anti-inflammatory and immunoregulatory medication used to treat multiple sclerosis (MS) and psoriasis. Its skin sensitization property precludes its topical use, which is unfortunate for the treatment of psoriasis. Isosorbide di-(methyl fumarate) (IDMF), a novel derivative of DMF, was synthesized to circumvent this adverse react…

Терапевтический потенциал диметилФумарата для обработки высококалорийной/высокосортной диетологической ожиренией.

Ожирение характеризуется несбалансированностью между потреблением энергии и расходами, которая вызывает ненормальный рост жировых тканей. Диметилфумарат (ДМП) и его первичный активный метаболит монометилфумарат (ММФ) являются активаторами Nrf2 и признаны в качестве стратегических антиоксидантов. Цель этого исследования состояла в том, чтобы оценить потенциал MMF и DMF в плане воздействия на адипогенез и ожирение, а также выявить соответствующие молекулярные механизмы. Предадипоциты 3T3-L1 были инкубированы с дифференциальной среды (MIX) и одновременно обработаны различными концентрациями MMF.

Совпадение в аннотации оригинала
Obesity is characterized by an imbalance between energy intake and expenditure that triggers abnormal growth of adipose tissues. Dimethyl fumarate (DMF) and its primary active metabolite, monomethyl fumarate (MMF), are Nrf2 activators and have been recognized as strategic antioxidants. This study aimed to evaluate the potential of MMF and DMF to interfere wi…

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis.

Mounting evidence points towards a pivotal role of gut microbiota in multiple sclerosis (MS) pathophysiology. Yet, whether disease-modifying treatments alter microbiota composition and whether microbiota shape treatment response and side-effects remain unclear. In this prospective observational pilot study, we assessed the effect of dimethyl fumarate (DMF) on gut microbiota and on host/microbial metabolomics in a cohort of 20 MS patients. Combining state-of-the-art microbial sequencing, metabolome mass spectrometry, and computational analysis, we identified longitudinal changes in gut microbio…

Inhibiting inflammation and modulating oxidative stress in oxalate-induced nephrolithiasis with the Nrf2 activator dimethyl fumarate.

Hyperoxaluria induces oxidative stress, and inflammation causes renal epithelial cell injury in nephrolithiasis, suggesting that reduced oxalate toxicity may be beneficial. This study aimed to investigate whether nuclear factor (erythroid-derived 2)-like 2 (Nrf2, also called Nfe2l2) induced by dimethyl fumarate (DMF) could protect renal epithelial cells against oxalate-mediated injury both in vivo and in vitro. Glyoxylic acid monohydrate was intraperitoneally injected into Sprague-Dawley rats with or without intragastric administration of DMF. We showed that calcium oxalate crystallisation, ac…

Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).

BACKGROUND: No therapies have been formally approved by the Food and Drug Administration for use in pediatric multiple sclerosis, a rare disease. OBJECTIVE: We evaluated the safety, efficacy, and pharmacokinetics of dimethyl fumarate in pediatric patients with multiple sclerosis. METHODS: FOCUS, a phase 2, multicenter study of patients aged 10 to 17 years with relapsing-remitting multiple sclerosis, comprised an eight-week baseline and 24-week treatment period; during treatment, patients received dimethyl fumarate (120 mg twice daily on days one to seven; 240 mg twice a day thereafter). Magn…

Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate.

BACKGROUND: Certain disease-modifying drugs for multiple sclerosis are known to be ineffective in treating neuromyelitis optica spectrum disorder (NMOSD), and can even induce subsequent relapses. CASE PRESENTATION: Here, we report on a patient with NMOSD who was misdiagnosed with multiple sclerosis and experienced severe exacerbations 3 months following initiation of treatment with dimethyl fumarate. The patient developed severe relapse in the form of myelitis extending from the medulla down to the T1 vertebral level. Cord swelling seen as contrast enhancement on magnetic resonance imaging wa…

Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient.

BACKGROUND: Dimethyl fumarate (DMF) is approved as first line therapy for relapsing-remitting multiple sclerosis (RRMS). In some (3%) patients, DMF induces a marked lymphopenia. Herpes simplex encephalitis (HSE) may occur in lymphopenic subjects under treatment with immune-suppressive drugs. CASE PRESENTATION: We report a case of a 39-year-old female patient with RRMS that developed HSE temporally associated with a marked and sudden drop in lymphocyte count, from 1200/µl to 600/µl, in the peripheral blood. HSE DNA was demonstrated in the cerebrospinal fluid. HSE had the features that characte…

Vitamin-Derived Nanolipoidal Carriers for Brain Delivery of Dimethyl Fumarate: A Novel Approach with Preclinical Evidence.

Various oral treatment options have been reported for relapsing multiple sclerosis. Recently, dimethyl fumarate (DMF) has been approved for the management of the same. Though effective, DMF is associated with concerns like multiple dosing, patient incompliance, gastrointestinal flushing, lower brain permeation, and economic hurdles. Henceforth, the objective of the present study was to develop vitamin-based solid lipid nanoparticles (SLNs) for effective brain delivery of DMF with a promise of once-a-day dosing. The developed SLNs were characterized for micromeritics, morphology, entrapment eff…

Ретроспективное исследование 116 пациентов с множественным склерозом с диметилФумаратом в одиночном учреждении в Японии.

Во всем мире растет глобальная распространенность множественного склероза (МС). Несмотря на то, что было одобрено большое число методов лечения, направленных на изменение болезней, они могут привести к серьезным негативным явлениям, включая инфекционные заболевания. Диметилфумарат (ДМФ), иммуномодулятор, имеет благоприятную характеристику безопасности. В эту эпоху персональной терапии важно выбрать соответствующего ДМТ для отдельных пациентов. В ходе этого исследования была проведена оценка результатов лечения японскими пациентами с помощью MS. В период с 6 января 2013 года по 31 октября 2022

Совпадение в аннотации оригинала
Objective The global prevalence of multiple sclerosis (MS) is increasing worldwide. Although many disease-modifying therapies (DMTs) have been approved, they can cause serious adverse events, including infections. Dimethyl fumarate (DMF), an immunomodulator, has a favorable safety profile. In this era of personalized therapy, it is important to select an app…

Диметилфумарат способствует разложению HNF1B и подавляет прогрессирование чистой почечной карциномы.

Чистая почечная карцинома (ccRCC) является самым смертельным подтипом рака почек, и его варианты лечения по-прежнему ограничены. Поэтому необходимо срочно найти лечебные агенты для лечения CCRCC. Здесь мы показываем, что диметилфумарат (ДМФ), одобренное лекарство от множественных склерозов [1] и псориаза, может сдерживать распространение клеток ЦКЦК. Механистически, гепатоцитовый ядерный фактор 1β (HNF1B), коэффициент транскрипции, ярко выраженный в CCRCC, поддерживается DMF в остатках цистейна, что ведет к его протеасомальной деградации. Кроме того, HNF1B взаимодействует с протеином, связанны

Совпадение в аннотации оригинала
Clear cell renal cell carcinoma (ccRCC) is the most lethal subtype of renal cancer, and its treatment options remain limited. Therefore, there is an urgent need to discover therapeutic agents for ccRCC treatment. Here, we demonstrate that dimethyl fumarate (DMF), an approved medication for multiple sclerosis [1] and psoriasis, can inhibit the proliferation o…

Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic.

INTRODUCTION: Dimethyl fumarate (DMF) is approved as oral systemic treatment for moderate-to-severe psoriasis. Scarce evidence is available for DMF treatment in psoriatic patients at the time of COVID-19 pandemic. The objective of this study was to assess the long-term effectiveness and safety of DMF monotherapy in moderate-to-severe psoriasis during the COVID-19 pandemic period. METHODS: This multicenter, retrospective study included patients with moderate-to-severe psoriasis who had received a 48-week DMF treatment during the COVID-19 pandemic. Selected outcomes were: variation of mean PASI…

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis.

BACKGROUND: The aim of this observational study is to investigate the efficacy and safety of two approved oral disease-modifying therapies (DMTs) in patients with remitting-relapsing multiple sclerosis (RRMS): dimethyl fumarate (DMF) vs. teriflunomide (TRF). METHODS: A total of 159 RRMS patients (82 on TRF and 77 on DMF) were included. The expanded disability status scale (EDSS), confirmed disability improvement (CDI), confirmed disability progression (CDP), and annualized relapse rate (ARR) were evaluated for the two-year period prior to enrollment in our study. The drug-associated adverse e…

Timing dictates efficacy: evaluating the prophylactic and therapeutic potential of dimethyl fumarate against LPS-induced shock.

BACKGROUND: Acute kidney injury (AKI) is a serious and often fatal condition that is caused by endotoxemia as a result of systemic inflammation and uncontrolled oxidative stress. Although dimethyl fumarate (DMF) has shown to have immunomodulatory and antioxidant activity, its specific prophylactic and therapeutic activity in endotoxemia-induced AKI remains unclear. AIM: to study DMF's effect on endotoxemia-induced AKI in a mouse in vivo model. METHODS: We divided the mice (Swiss albino) into eight equal groups. The endotoxemia-induced AKI was treated by intraperitoneal injection with LPS (5 …

Dimethyl Fumarate Treatment for Psoriasis in Real-World Clinical Practice: An Analysis from the Swiss Registry.

INTRODUCTION: Limited data are available on the effectiveness and safety of dimethyl fumarate (DMF) for the treatment of moderate-to-severe psoriasis in real-world clinical practice. The objectives were to assess the effectiveness and safety of DMF in patients with moderate-to-severe plaque psoriasis in Switzerland. METHODS: Data from 28 adults enrolled in the Swiss Dermatology Network for Targeted Therapies registry who started DMF treatment as first line or subsequence therapy at registry entry and had ≥3 months of follow-up were analysed. No missing imputation was performed. RESULTS: The …

Диметилфумарат смягчает прогрессию остеоартрита путем активации Nrf2 с помощью средств подавления окислительного стресса и субхондрального остеоластогенеза.

Osteoarthritis (OA) — дегенеративное соеденительное заболевание, связанное с несбалансированной субхондральной реконструкцией костей, и в настоящее время лечебное лечение отсутствует. В ОА чрезмерная остеокластная активность приводит к потере костей и подстрекательским реакциям. Диметилфумарат (ДМФ) - активатор Nrf2, уже используемый при лечении псориаза и множественного склероза, - может облегчить ОА путем подавления окислительного стресса и остеокластогенеза. В этом исследовании изучается воздействие ДМФ на остеокласты, субхондральную кость, артикулярный хрящ и механизмы, лежащие в основе ра

Совпадение в аннотации оригинала
Osteoarthritis (OA) is a degenerative joint disease associated with imbalanced subchondral bone remodeling, and there is currently no curative treatment available. In OA, excessive osteoclast activity leads to bone loss and inflammatory responses. Dimethyl fumarate (DMF), an Nrf2 activator already used in treating psoriasis and multiple sclerosis, may allevi…

Вирус Варичелла-Зостер связан с васкулопатией у молодого склероза мужского пола, лечившегося диметилфумаратом.

По мере все более широкого использования болезней, изменяющих методы лечения в качестве лечения множественных склерозов, становится все более важным знание редких, но, возможно, серьезных негативных явлений. Мы представим случай вируса Вариселла-Зостер, связанного с васкулопатией у молодого парня, больного множественным склерозом, который лечился диметилфуматом. Мы стремимся устранить это редкое, но потенциально смертоносное осложнение вирусной инфекции варицелла-Зостер и распространять информацию о возросшем риске для этой пациентки.

Совпадение в аннотации оригинала
With the increasing use of disease modifying therapies as treatment for multiple sclerosis, knowledge of the rare but possibly severe adverse events becomes increasingly important. We present a case of Varicella-Zoster virus associated vasculopathy in a young male multiple sclerosis patient, treated with dimethyl fumarate. We aim to address this rare but pot…

Диметил фумарат отменяет гепатоцеллюлярный карциномный рост, подавляя ось Nrf2/Bcl-xL и повышая эффективность сорафениба.

Гепатоклеточная карцинома (ГК) характеризуется плохим прогнозом и остается одной из основных причин смертности от рака во всем мире. Усовершенствованный КЦУК регулируется несколькими методами лечения первой линии, включая ингибиторы тиросина киназы (TKI) и иммунную терапию (mAb-PD-1 и mAb-VEGF). Вместе с тем эффективность лечения КЦХВ зачастую недолговечна. Недавние исследования показали, что активация траектории Nrf2-Bcl-xL способствует плохому прогнозу у группы пациентов с КЦХВ. Здесь мы обнаружили, что диметилфумарат (DMF), лекарство, используемое для лечения псориаза и множественного склер

Совпадение в аннотации оригинала
Hepatocellular carcinoma (HCC) is characterized by poor prognosis and remains a leading cause of cancer mortality worldwide. Advanced HCC is … Nrf2-Bcl-xL pathway contributes to poor prognosis in a subset of HCC patients. Here, we found that dimethyl fumarate (DMF), a drug used for treating psoriasis and multiple sclerosis, regulates the Nrf2-Bcl-xL signaling axis to inhibit HCC growth in a mice xenograft model. Mechanistically, the downregulation of the Nrf2-Bcl-xL axis led to mitochondria stress and ap …